Examples of using Persistent asthma in English and their translations into Polish
{-}
-
Medicine
-
Colloquial
-
Official
-
Ecclesiastic
-
Ecclesiastic
-
Financial
-
Official/political
-
Programming
-
Computer
Xolair is used to improve the control of severe persistent asthma that is caused by an allergy.
A study to evaluate safety andefficacy of mepolizumab in patients with moderate persistent asthma.
The diagnosis of persistent asthma in very young children(6 months- 2 years) should be established by a paediatrician or pulmonologist.
Editor's comment: Three physicians' comments on various treatment options for mild, persistent asthma are included.
Developed with the intent of dealing with persistent asthma, Clen is also an effective fat-burner with some similarities to Ephedrine yet much more strongly reliable.
Xolair treatment should be initiated by a doctor who has experience in the treatment of severe persistent asthma.
The study was conducted in a group of four patients with severe persistent asthma treated with conventional therapy(according to GINA 2006) and further treated with omalizumab.
Xolair treatment should be initiated by physicians experienced in the diagnosis andtreatment of severe persistent asthma.
If you have severe persistent asthma, COPD or are a heavy smoker, you should discuss with your doctor whether treatment with a TNF blocker is appropriate for you.
Xolair treatment should be started by a doctor who has experience in the treatment of severe persistent asthma or chronic spontaneous urticaria.
Mild persistent asthma is defined as asthma symptoms more than once a week but less that once a day, nocturnal symptoms more than twice a month but less than once a week, normal lung function between episodes.
In 2 to5 year old patients, exercise-induced bronchoconstriction may be the predominant manifestation of persistent asthma that requires treatment with inhaled corticosteroids.
Use in adolescents and adults(12 years of age and older) Xolair treatment should be initiated by physicians experienced in the diagnosis andtreatment of severe persistent asthma.
In 2 to 5 year old patients, exercise-induced bronchoconstriction may be the predominant manifestation of persistent asthma that requires treatment with inhaled corticosteroids.
Therefore, the PDCO expressed the need to conduct studies to precisely define the patient population that should receive montelukast sodium for the treatment of mild persistent asthma.
In an exploratory clinical trial evaluating the use of Simponi in patients with severe persistent asthma, more malignancies were reported in patients treated with Simponi compared with control patients see section 4.8.
The results of P910 suggest that with montelukast, as good benefit-risk ratio can be achieved in the treatment of paediatric mild, persistent asthma as with inhaled fluticasone.
In controlled Phase IIb and/or III trials in RA, PsA, AS, nr-Axial SpA,severe persistent asthma, and Phase II/III trials in UC, no patients treated with golimumab developed anaphylactic reactions.
Four additional large placebo-controlled supportive studies of 28 to 52 weeks duration in 1,722 adults and adolescents(studies 3, 4, 5, 6)assessed the efficacy and safety of Xolair in patients with severe persistent asthma.
The results of this study suggest that Viani 50/ 100mcg bd may be considered as initial maintenance therapy in patients with moderate persistent asthma for whom rapid control of asthma is deemed essential see section 4.2.
The issue to be considered by CHMP was whether it is appropriate to introduce initial maintenance therapy with the fixed dose combination of salmeterol andfluticasone propionate in all patients with chronic persistent asthma.
A short term trial of Viani may be considered as initial maintenance therapy in adults or adolescents with moderate persistent asthma(defined as patients with daily symptoms, daily rescue use and moderate to severe airflow limitation) for whom rapid control of asthma is essential.
On the basis of the grounds for referral, the point considered by the CHMP was whether it is appropriate to introduce initial maintenance therapy with the fixed dose combination of salmeterol andfluticasone propionate in all patients with chronic persistent asthma.
A short term trial of Seretide may be considered as initial maintenance therapy in adults or adolescents with moderate persistent asthma(defined as patients with daily symptoms, daily rescue use and moderate to severe airflow limitation) for whom rapid control of asthma is essential.
The MAHs applied for a type II variation subject to MRP to extend the current approved indications to include initial maintenance therapy(IMT) with the fixed dose combination in patients with chronic persistent asthma.
The MAHs have demonstrated in a series of substantial andwell conducted clinical studies that in patients with moderate chronic persistent asthma poorly controlled on a short acting β-agonist alone the introduction of combination therapy with salmeterol and fluticasone is more effective in improving disease control than the introduction of salmeterol or fluticasone alone.
Xolair treatment should be initiated by physicians experienced in the diagnosis andtreatment of severe persistent asthma or chronic spontaneous urticaria.
The MAH' s proposed therapeutic indication to include“ patients with persistent asthma not adequately controlled on"as needed" inhaled short- acting beta-2-agonists alone who exhibit a combination of at least two of the following clinical features of asthma: airflow limitation, daily use of rescue medication, daily symptoms(day-time and/ or night-time)” was not considered acceptable as it does not effectively identify a population in need of combination therapy.
The recommendation included in section 4.2 allows a short term trial of Viani Diskus in adults andadolescents with moderate persistent asthma for whom rapid control of asthma is essential.
The Marketing Authorisation Holders submitted a type II variation subject to the MRP in July 2004 to extend the indication to include initial maintenance therapy with the fixed dose combination in patients with chronic persistent asthma.